Advances in AIDS vaccine developmentAIDS research and human retroviruses. 1994, Vol 10, pp S1-S342, issn 0889-2229, SUP2Conference Proceedings

Panel discussion on vaccine development to meet U.S. and international needs. Perspectives on national and global HIV vaccine development : potential ways to reduce impediments for biopharmaceutical product developmentOBIJESKI, J.AIDS research and human retroviruses. 1994, Vol 10, pp S307-S308, issn 0889-2229, SUP2Conference Paper

HIV vaccines for injection drug users in the context of a comprehensive prevention agendaVLAHOV, D.AIDS research and human retroviruses. 1994, Vol 10, pp S3-S6, issn 0889-2229, SUP2Conference Paper

Panel discussion on vaccine development to meet U.S. and international needs. Strategies for reducing the disincentives to HIV vaccine development description of a successful public-private sector international collaborationBRONNENKANT, L.AIDS research and human retroviruses. 1994, Vol 10, pp S311-S313, issn 0889-2229, SUP2Conference Paper

Preparations for AIDS vaccine evaluations. AIDS international training and research programBRIDBORD, K.AIDS research and human retroviruses. 1994, Vol 10, pp S227-S229, issn 0889-2229, SUP2Conference Paper

Preparations for HIV vaccine trials : moving from baseline studies to efficacy trialsHOFF, R.AIDS research and human retroviruses. 1994, Vol 10, pp S191-S193, issn 0889-2229, SUP2Conference Paper

Phase I/II trials of preventive HIV vaccine candidates. Dose and schedule : summaryGORSE, G. J.AIDS research and human retroviruses. 1994, Vol 10, pp S141-S143, issn 0889-2229, SUP2Conference Paper

Preparations for AIDS vaccine trials respecting concerns of international host countriesKATONGOLE-MBIDDE, E.AIDS research and human retroviruses. 1994, Vol 10, pp S187-S189, issn 0889-2229, SUP2Conference Paper

Panel discussion on vaccine development to meet U.S. and international needs. When manufacturers are unwilling to accept the risks or invest the capital : vaccine production by the salk institute to specifications of the U.S. ArmyFRENCH, G. R.AIDS research and human retroviruses. 1994, Vol 10, issn 0889-2229, p. S309, SUP2Conference Paper

Towards a preventive HIV vaccine-lessons from historyTRAMONT, E. C.AIDS research and human retroviruses. 1994, Vol 10, pp S181-S185, issn 0889-2229, SUP2Conference Paper

Behavioral research contributions to planning and conducting HIV vaccine efficacy studiesTEMOSHOK, L. R.AIDS research and human retroviruses. 1994, Vol 10, pp S277-S280, issn 0889-2229, SUP2Conference Paper

Overview : HIV vaccine feasibility studiesSHEON, A. R.AIDS research and human retroviruses. 1994, Vol 10, pp S195-S196, issn 0889-2229, SUP2Conference Paper

Serological responses to candidate AIDS vaccinesGRAHAM, B. S.AIDS research and human retroviruses. 1994, Vol 10, pp S145-S148, issn 0889-2229, SUP2Conference Paper

Preparations for AIDS vaccine trials. Recruitment and retention of in- and out-of-treatment injection drug usersWOODY, G. E; METZGER, D; MULVANEY, F et al.AIDS research and human retroviruses. 1994, Vol 10, pp S197-S199, issn 0889-2229, SUP2Conference Paper

Mucosal immunity in the female genital tract : relevance to vaccination efforts against the human immunodeficiency virusMESTECKY, J; KUTTEH, W. H; JACKSON, S et al.AIDS research and human retroviruses. 1994, Vol 10, pp S11-S20, issn 0889-2229, SUP2Conference Paper

Seroprevalence and seroincidence of HIV-1 in injection drug users using the VA systemMARTIGAN, P. M; HAMILTON, J. D.AIDS research and human retroviruses. 1994, Vol 10, pp S215-S217, issn 0889-2229, SUP2Conference Paper

Cytotoxic T lymphocytes induced by liposomal antigens : mechanisms of immunological presentationALVING, C. R; WASSEF, N. M.AIDS research and human retroviruses. 1994, Vol 10, pp S91-S94, issn 0889-2229, SUP2Conference Paper

Behavioral studies relevant to vaccine trial preparation : an introductionTURNER, C. F; SHEON, A. R.AIDS research and human retroviruses. 1994, Vol 10, pp S273-S276, issn 0889-2229, SUP2Conference Paper

Preparations for AIDS vaccine evaluations. Progress in international cohort development and evaluationFISCHER, R. D; MCNEIL, J. G.AIDS research and human retroviruses. 1994, Vol 10, pp S223-S225, issn 0889-2229, SUP2Conference Paper

Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccine in HIV-1 uninfected individualsMCELRATH, M. J; COREY, L; GREENBERG, P. D et al.AIDS research and human retroviruses. 1994, Vol 10, pp S69-S72, issn 0889-2229, SUP2Conference Paper

Mechanisms of action of nonionic block copolymer adjuvantsHUNTER, R. L; MCNICHOLL, J; LAL, A. A et al.AIDS research and human retroviruses. 1994, Vol 10, pp S95-S98, issn 0889-2229, SUP2Conference Paper

Effect of mutations in rev gene of SIV_mac on virus replicationAAVIK, E; HAKKARAINEN, K; KROHN, K. J. E et al.AIDS research and human retroviruses. 1994, Vol 10, pp S123-S128, issn 0889-2229, SUP2Conference Paper

Feasibility and cohort development for HIV vaccine trial in HaitiDESCHAMPS, M. M; JOHNSON, W. D; PAPE, J. W et al.AIDS research and human retroviruses. 1994, Vol 10, pp S231-S233, issn 0889-2229, SUP2Conference Paper

Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trialRUBINSTEIN, A; GOLDSTEIN, H; PETTOELLO-MANTOVANI, M et al.AIDS research and human retroviruses. 1994, Vol 10, pp S149-S153, issn 0889-2229, SUP2Conference Paper

Dicistronic polioviruses as expression vector for foreign genesALEXANDER, L; HUI HUA LU; GROMEIER, M et al.AIDS research and human retroviruses. 1994, Vol 10, pp S57-S60, issn 0889-2229, SUP2Conference Paper